Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP
Key Highlights
- ➤$25 million acquisition adds WoundSkan and Spektra medical technology IP
- ➤Consideration includes $2.5 million cash and 1,730,770 new shares
- ➤New shares fixed at $13.00 each, issued after January 20, 2027 listing
- ➤WoundSkan monitors wound temperature through a battery-free NFC dressing
- ➤Spektra delivers two-minute multi-marker screening via smartphone-connected cartridges
Expert Statements
Glenn Williams, Chief Executive Officer of Davion Healthcare
“This acquisition is an important step in our plans to build a substantial international healthcare business, combining the development of our existing portfolio with the acquisition of complementary technologies.”
Glenn Williams, Chief Executive Officer of Davion Healthcare
“WoundSkan and Spektra are both innovative, practical technologies with considerable commercial potential. WoundSkan builds on our existing expertise in temperature-based monitoring, offering a way to assess wounds without removing dressings, while Spektra provides rapid screening for multiple conditions from a single sample. Both have applications across a range of healthcare settings.”
Glenn Williams, Chief Executive Officer of Davion Healthcare
“Following our recent Nasdaq listing, we are well positioned to accelerate the development and commercialisation of these technologies, while continuing to pursue further acquisition opportunities.”
DUBLIN, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (Nasdaq: DAVI) ("Davion" or the "Company"), a next-generation digital healthcare company developing proprietary health monitoring technologies, today announces that it has completed the acquisition of the intellectual property relating to two medical technologies: WoundSkan, a smart wound-monitoring dressing, and the Spektra Lateral Flow Test, a rapid multi-marker screening platform.
The intellectual property was acquired from the four shareholders of Humaskan Ltd for a total consideration of US$25 million, comprising US$2.5 million in cash and 1,730,770 new ordinary shares in Davion, to be issued at an agreed fixed contractual value of US$13.00 per share (approximately US$22.5 million). The number of shares is fixed and will not vary with movements in the Davion's share price.
Get started
Create a free account to read the full story.